tbuckley/cabot-search huggingface dataset:
COP26 diary: Health at last get its big day (well, hour)
Authors: Richard Smith
Journal: BMJ (2021)

#### Tuesday 9 November

Today is my last day at COP26, and I’m full of admiration for those people who stick out the whole two weeks. I’d go crazy. But today is a special day, it’s science day—and health has been squeezed into the programme. Patricia Espinosa, the executive secretary of the United Nations Framework Convention on Climate Change, and Sajid Javid, the UK’s Secretary of State for Health and Social Care, are expected to attend a one-hour session on health.

We, the health people, are excited that our day has come, and we start queuing for seats some 40 minutes before the session is to begin. We have the satchel brought by cycling health professionals from Geneva to Glasgow and a cardboard poster summarising the healthy prescription letter. The hope of being able to present both to Alok Sharma, the COP26 president, is fading, but Espinosa is second choice. We are to be granted two minutes at the beginning to be photographed with Espinosa. As I’m the only person available who did any of the cycling (and I did only one day) it’s my job to grab Espinosa and be photographed with her. (It proved impossible to get any of the people who cycled all the way from London to Glasgow into the Blue Zone, and I’m only here because the Royal College of Psychiatrists had a spare space and kindly gave it to me.)

While in the queue we discuss breastfeeding, a discussion sparked by the observation that there are no babies—and almost no children—at COP26. Both the women I’m talking with have experience of breastfeeding, but we agree that it is becoming more difficult to breastfeed in public, perhaps explaining the lack of babies at COP26.

At last, the doors open, and we look for somebody to be photographed with. Unfortunately—but …
Plasma NTPDase1 Activity Regulates Platelet Purinergic Signaling in Sickle Cell Disease
Authors: Tomasz Brzoska, Elizaveta V Menchikova, Tomasz W. Kaminski, Ravi Vats, Egemen Tutuncuoglu, Stevan P. Tofovic, Edwin K. Jackson, Mark T. Gladwin, Prithu Sundd
Journal: Blood (2021)
The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years — United States, November 2021
Authors: Kate R. Woodworth, Danielle Moulia, Jennifer P. Collins, Stephen C. Hadler, Jefferson M. Jones, Sujan C. Reddy, Mary Chamberland, Doug Campos-Outcalt, Rebecca L. Morgan, Oliver Brooks, H. Keipp Talbot, Grace M. Lee, Beth P. Bell, Matthew F. Daley, Sarah Mbaeyi, Kathleen Dooling, Sara E. Oliver
Journal: MMWR Morbidity and Mortality Weekly Report (2021)

The Pfizer-BioNTech COVID-19 (BNT162b2) vaccine is a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. On August 23, 2021, the Food and Drug Administration (FDA) approved a Biologics License Application (BLA) for use of the Pfizer-BioNTech COVID-19 vaccine, marketed as Comirnaty (Pfizer, Inc.), in persons aged ≥16 years (1). The Pfizer-BioNTech COVID-19 vaccine is also recommended for adolescents aged 12-15 years under an Emergency Use Authorization (EUA) (1). All persons aged ≥12 years are recommended to receive 2 doses (30 μg, 0.3 mL each), administered 3 weeks apart (2,3). As of November 2, 2021, approximately 248 million doses of the Pfizer-BioNTech COVID-19 vaccine had been administered to persons aged ≥12 years in the United States.* On October 29, 2021, FDA issued an EUA amendment for a new formulation of Pfizer-BioNTech COVID-19 vaccine for use in children aged 5-11 years, administered as 2 doses (10 μg, 0.2 mL each), 3 weeks apart (Table) (1). On November 2, 2021, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation† for use of the Pfizer-BioNTech COVID-19 vaccine in children aged 5-11 years for the prevention of COVID-19. To guide its deliberations regarding recommendations for the vaccine, ACIP used the Evidence to Recommendation (EtR) Framework§ and incorporated a Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach.¶ The ACIP recommendation for the use of the Pfizer-BioNTech COVID-19 vaccine in children aged 5-11 years under an EUA is interim and will be updated as additional information becomes available. The Pfizer-BioNTech COVID-19 vaccine has high efficacy (>90%) against COVID-19 in children aged 5-11 years, and ACIP determined benefits outweigh risks for vaccination. Vaccination is important to protect children against COVID-19 and reduce community transmission of SARS-CoV-2.
THE DISCONTINUATION OF NUCLEOS(T)IDE ANALOGUE TREATMENT IS NOT ASSOCIATED WITH HIGHER RISK OF HBsAg-SEROREVERSION AFTER ANTIVIRAL-INDUCED HBsAg-SEROCLEARANCE: A MULTICENTER COHORT STUDY
Authors: Kim, MA[Kim, Minseok Albert], Lee, JH[Lee, Jeong-Hoon], Lim, YS[Lim, Young-Suk], Kim, SU[Kim, Seung Up], Sinn, DH[Sinn, Dong Hyun], Park, Y[Park, Yewan], Kim, SG[Kim, Sang Gyune], Baek, YH[Baek, Yang Hyun], Kim, JH[Kim, Ji Hoon], Shim, JJ[Shim, Jae-Jun], Jang, JY[Jang, Jae Young], Jang, H[Jang, Heejoon], Oh, H[Oh, Hyunwoo], Kim, SW[Kim, Sun Woong], Lee, CH[Lee, Cheol-Hyung], Lee, YB[Lee, Yun Bin], Cho, EJ[Cho, Eun Ju], Yu, SJ[Yu, Su Jong], Kim, YJ[Kim, Yoon Jun], Yoon, JH[Yoon, Jung-Hwan]
Journal: Hepatology (2019)
Inhibition of <i> De Novo</i> Pyrimidine Synthesis Depletes Acute Myleogenous Leukemia Stem Cells (LSCs) Burden and Triggers Apoptosis and Differentiation Associated with Oxidative Stress
Authors: Sujan Piya, Huaxian Ma, Priyanka Sharma, Kensuke Kojima, Vivian Ruvolo, Mahesh Basyal, Natalia Baran, Marla Weetall, Josephine Sheedy, Balmiki Ray, Michael Andreeff, Gautam Borthakur
Journal: Blood (2021)
Diversity, equity, and inclusion in academia to guide society
Authors: Akira S. Mori
Journal: Trends in Ecology & Evolution (2021)

Many barriers exist in academia. Shedding light on scholars from marginalized groups is important for scientific publishing and policy–science dialogs to ensure equity, beyond merely aiming to increase the numbers to achieve equality. Achieving diversity, inclusiveness, and equality in academia is not the goal, but an essential means of realizing a sustainable future.
Phase II Study of Venetoclax Added to Cladribine (CLAD) and Low Dose AraC (LDAC) Alternating with 5-Azacytidine (AZA) in Older and Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
Authors: Patrick K Reville, Hagop Kantarjian, Gautam Borthakur, Naveen Pemmaraju, Courtney D. DiNardo, Koji Sasaki, Naval Daver, Ghayas C. Issa, Maro Ohanian, Guillermo Montalban-Bravo, Nicholas J. Short, Nitin Jain, Kapil N. Bhalla, Elias J. Jabbour, Alessandra Ferrajoli, Koichi Takahashi, Caitlin R. Rausch, Rashmi Malla, Kelly Marek, Mark Brandt, Uday R. Popat, Michael Andreeff, Guillermo Garcia-Manero, Marina Konopleva, Farhad Ravandi, Tapan M. Kadia
Journal: Blood (2021)
Minimal Toxicity Seen When Pembrolizumab Is Added to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: Early Results from an Ongoing Phase II Trial (ECOG-ACRIN EA9171)
Authors: Amer M. Zeidan, Kevin Roopcharan, Jerry P. Radich, Jan Philipp Bewersdorf, Vijaya R. Bhatt, Elad Sharon, Richard F. Little, Steven D. Gore, Anne Caldwell, Selina M. Luger, Mark R. Litzow
Journal: Blood (2021)
Patients with AML Who Achieve Long Term Complete Remission Do Not Have a Normal Life Expectancy When Compared to the General Population. Analysis of 3,012 Patients Enrolled on 9 Consecutive ECOG-ACRIN Trials
Authors: Chezi Ganzel, Kevin Roopcharan, Zhuoxin Sun, Jacob M. Rowe, Hugo F Fernandez, Elisabeth M. Paietta, Selina M. Luger, Hillard M Lazarus, Larry D Cripe, Dan Douer, Peter H. Wiernik, Martin S. Tallman, Mark R. Litzow
Journal: Blood (2021)
Abstract 9434: Cigarette Smoking and Incident Heart Failure With Preserved Ejection Fraction in African Americans: The Jackson Heart Study
Authors: Daisuke Kamimura, Robert J Mentz, Amil M Shah, Adebamike A Oshunbade, Arsalan Hamid, Takeki Suzuki, Donald Clark, Ervin R Fox, Adolfo Correa, Javed Butler, Michael E Hall
Journal: Circulation (2021)

Background: Cigarette smoking has been associated with incident heart failure (HF), however the relationships with HF phenotypes have not been adequately investigated, particularly in African Americans. Methods and Results: Among 4129 African Americans participants in the Jackson Heart Study without a history of HF or coronary heart disease (CHD) at baseline, we investigated the relationships between baseline smoking status, smoking intensity (number of cigarettes/day) among current smokers, and smoking burden (pack years) among ever smokers and incident HF hospitalization. HF phenotypes were categorized either as HF with reduced ejection fraction (HFrEF: EF&lt;50%) or HF with preserved EF (HFpEF: EF≥50%). There were 2884 (70%) never smokers, 503 (12%) current smokers, and 742 (18%) former smokers. Over a median of 11.0 years follow-up (interquartile range: 10.4-11.0), there were 215 incident HF hospitalizations (95 incident HFrEF, 120 incident HFpEF). After adjustment for traditional risk factors of age, sex, body mass index, systolic blood pressure, anti-hypertensive medication, diabetes, estimated glomerular filtration rate, and incident CHD, current smoking was associated with incident HFpEF (hazard ratio, 3.21; 95% confidence interval, 1.80-5.71), but not with incident HFrEF in comparison with never smokers. Smoking intensity among current smokers (hazard ratio, 1.06 per 1 cigarette/day; 95% confidence interval, 1.02-1.09), and smoking burden among ever smokers (hazard ratio, 1.08 per 10 pack-years; 95% confidence interval, 1.01-1.16) were also significantly associated with incident HFpEF but not with incident HFrEF (Table). Conclusion: In this large community-based African American cohort, cigarette smoking (smoking status, smoking intensity, and smoking burden) was significantly associated with incident HFpEF, but not with HFrEF. Smoking cessation in African Americans who smoke may reduce risk for HFpEF in this high-risk population.
Immunomodulation and RNA interference alter hepatitis B virus–specific CD8 T‐cell recognition of infected HepG2‐NTCP
Authors: Adrian Kuipery, Juan Diego Sanchez Vasquez, Aman Mehrotra, Jordan J. Feld, Harry L. A. Janssen, Adam J. Gehring
Journal: Hepatology (2021)

Abstract Background and Aims CD8 T cells are essential in controlling HBV infection. Viral control is dependent on efficient recognition of HBV‐infected hepatocytes by CD8 T cells, which can induce direct lysis of infected hepatocytes. In addition, CD8 T cells produce interferon (IFN)‐γ, which mediates noncytopathic viral clearance. Innate immunomodulators and HBV‐targeted RNA interference (RNAi) are being developed to treat chronic hepatitis B (CHB), but may modify HBV antigen presentation and impact CD8 T‐cell recognition, in addition to their primary mechanisms of action. Approach and Results HBV‐infected HepG2‐NTCP cells were treated with tenofovir disoproxil fumarate (TDF), Toll‐like receptor (TLR) 7/8 agonists, TLR7/8 conditioned media (CM) collected from immune cells, or RNAi using short interfering RNAs. The effect of these treatments on antigen presentation was measured through coculture with CD8 T cells recognizing human leukocyte antigen–A0201 restricted epitopes, HBc18‐27 or HBs183‐191. Cytokine profiles of TLR7/8 CM were measured using a cytometric bead array. TDF reduced viral replication, but not CD8 T‐cell recognition, of infected cells. Direct exposure of infected HepG2‐NTCP to TLR7/8 agonists had no impact on T‐cell recognition. Exposure of infected HepG2‐NTCP to TLR7/8 CM enhanced HBV‐specific CD8 T‐cell recognition through type 1 interferon (IFN) and IFN‐γ‐dependent mechanisms. RNAi rapidly suppressed HBV‐DNA, HBcAg, and HBsAg expression, impairing recognition by HBV‐specific CD8 T cells. Conclusions Immunomodulation and RNAi, but not nucleos(t)ide analogues, alter the recognition of infected HepG2‐NTCP by HBV‐specific CD8 T cells. Understanding these changes will inform combination treatments for CHB.
Allogeneic Hematopoietic Cell Transplantation Outcomes of Patients with R/R AML or Higher-Risk MDS Treated with the TIM-3 Inhibitor MBG453 (Sabatolimab) and Hypomethylating Agents
Authors: Andrew M. Brunner, Elie Traer, Norbert Vey, Sebastian Scholl, Natalia Tovar, Kimmo Porkka, Rupa Narayan, Guillermo Garcia-Manero, Steve Knapper, Martin Wermke, Jeroen J. Janssen, Jordi Esteve, Sun Loo, Mika Kontro, Zachariah Defilipp, Andrew H. Wei, Uma Borate
Journal: Blood (2021)
Peripheral Blood Haploidentical Allogeneic Stem Cell Transplantation in Older Adults with AML/MDS Demonstrates Excellent Long Term Overall Survival, Results from the Australasian Bone Marrow Transplant Recipient Registry
Authors: Edward Abadir, Jad Othman, John Kwan, David J Gottlieb, Glen A Kennedy, Ashish Bajel, Richard Doocey, Travis Perera, Anne-Marie Watson, Peter G Bardy, Matthew Greenwood, David J. Curtis, Steven Tran, John Moore, Nada Hamad
Journal: Blood (2021)
Optimisation of peanut protein crosslinking by oxidase and transglutaminase enzymes and the effects on IgE binding
Authors: Ljiljana Mihajlović-Lalić, Jelena Radosavljević, Emilia Nordlund, Joost Smit, Johanna Buchert, Tanja Ćirković-Veličković
Journal: Allergy (2011)
Abstract 13657: Malignant Multivessel Coronary Spasm
Authors: Ana Inashvili, Ruifang Yang, Benjamin Kilpatrick, David Goldgrab, Hector Garza, Devansh Patel, Tehreen Khan, Robert M Dewhurst, Stephen Mester, William Bugni
Journal: Circulation (2021)

Objective: Management of multivessel coronary spasm is challenging. Case: A 59-year-old female with a medical history of CAD status post coronary stents presented with atypical chest pain.The following morning the patient suffered a PEA arrest, from which she was resuscitated. Retrospective review of telemetry revealed frequent episodes of transient ST segment elevations in inferior leads, lasting minutes, eventually followed by sinus bradycardia and episodes of high-degree AV block with pauses up to 20 seconds.Two weeks earlier the patient presented at another institution with similar complaints. Inferior STEMI was diagnosed, she received 2 DES, in proximal OM1 and Mid LAD. She represented 6 days later with continued symptoms and repeat catheterization revealed patent stents. She was reassured and discharged on Isosorbide Mononitrate in addition to Carvedilol. Management and Decision Making: Coronary angiography at our facility demonstrated 90% stenosis of proximal LCX and 60-70% of proximal LAD. These stenosis resolved with intracoronary nitroglycerin. The stents were patent. Therefore, she was diagnosed with coronary spasm. During her hospital stay, the patient did have four more episodes of ST elevations associated with complete heart block. Since she developed high degree AV block after a coronary spasm, a temporary pacemaker was placed. Norvasc as well as nitroglycerin drip were used to treat her coronary vasospasm. Pure B-blocker medications were avoided to prevent unbalanced alpha effect.The patient was extubated 4 days later and fully recovered neurologically. A permanent pacemaker was placed and discharged home. Conclusion: High suspicion is important for diagnosis of coronary vasospasm. Treatment with coronary vasodilators is cornerstone of management. We also avoided pure alpha agonists during resuscitation measures, as well as pure B-blocker medications after recovery.
Abstract 9153: Predictive and Protective Factors of Early, Late, and Very Late Stent Thrombosis in Acute Coronary Syndrome Patients Undergoing Coronary Stent Implantation: Findings from the Atlas Acs 2-timi 51 Trial
Authors: Gerald Chi, Fahad Alkhalfan, Jane J Lee, Sahar Memar Montazerin, Clara Fitzgerald, Serge Korjian, Wally Omar, Elliot Barnathan, Alexei Plotnikov, Eugene Braunwald, C. Michael Gibson
Journal: Circulation (2021)

Introduction: Stent thrombosis (ST) is an uncommon but serious complication of stent implantation. The aim of this analysis was to explore predictive and protective factors of early, late, and very late ST. Methods: This was a post-hoc analysis of the ATLAS ACS 2-TIMI 51 trial, which included acute coronary syndrome patients who received stent placement. Incidence of ST was assessed by Kaplan-Meier estimates at 30 days, 31 to 360 days, 361 to 720 days, and up to 720 days, with day 1 defined as the day of stent implantation. Multivariable associations with ST were explored by fitting Cox proportional hazards models. The covariates included patient characteristics, baseline laboratory tests (i.e., cardiac biomarkers, hemoglobin, platelet count, white blood cell [WBC]), and ST treatment (i.e., drug-eluting stent [DES] vs. bare-metal stent and anticoagulant with rivaroxaban vs. placebo). Results: Among 8,741 stented patients, a total of 155 ST events (2.25%) occurred by day 720. The cumulative incidence of early, late, and very late ST was 0.80%, 0.81%, and 0.77%, respectively. After multivariable adjustment, age ≥75 years (HR=2.13 [95% CI: 1.26-3.60]), a history of prior myocardial infarction (MI) (HR=1.81 [95% CI: 1.22-2.68]), low hemoglobin (HR=2.34 [95% CI: 1.59-3.44]), high WBC (HR=1.58 [95% CI: 1.02-2.46]), DES (HR=0.56 [95% CI: 0.38-0.83]), and rivaroxaban (HR=0.63 [95% CI: 0.44-0.88]) were associated with overall ST. Low hemoglobin (HR=2.35 [95% CI: 1.34-4.12]) and high WBC (HR=2.11 [95% CI: 1.17-3.81]) were predictive of early ST. Low hemoglobin (HR=2.32 [95% CI: 1.26-4.27]), prior MI (HR=2.98 [95% CI: 1.67-5.31]), and DES (HR=0.33 [95% CI: 0.16-0.67]) were associated with late ST. Age ≥75 years was predictive of very late ST (HR=3.71 [95% CI: 1.12-12.3]). Conclusions: The study identified factors with positive and negative associations with early, late, and very late ST that may be useful in constructing risk assessment models for ST.
Development of Notch1 Positive T-Lineage Lymphomas or Splenic Marginal Zone Lymphomas with Pan-Hematopoietic or Pro-B Cell Specific Deletion of Trp53 with Distinct Differentially Dysregulated Pathways
Authors: Jayanth Kumar Palanichamy, Tiffany Tran, Jennifer King, Sol Katzman, Gunjan Sharma, Christine Tso, Jorge R Contreras, Thilini Fernando, Jeremy Sanford, Dinesh S Rao
Journal: Blood (2021)
Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B Cell Precursor Acute Lymphoblastic Leukemia
Authors: Lennart Lenk, Dorothee Winterberg, Fotini Vogiatzi, Anna Laqua, Lea Spory, Ahmad Mayar, Christian Vokuhl, Julia Richter, Michela Carlet, Irmela Jeremias, Thomas Valerius, Martin Schrappe, Gunnar Cario, Hassan Jumaa, Elias Hobeika, Monika Brüggemann, Ameera Alsadeq, Denis Martin Schewe
Journal: Blood (2021)
Nucleic Acid Delivery from Granular Hydrogels
Authors: Evan Kurt, Tatiana Segura
Journal: Advanced Healthcare Materials (2021)

Nucleic acid delivery has applications ranging from tissue engineering to vaccine development to infectious disease. Cationic polymer condensed nucleic acids are used with surface-coated porous scaffolds and are able to promote long-term gene expression. However, due to surface loading of the scaffold, there is a limit to the amount of nucleic acid that can be loaded, resulting in decreasing expression rate over time. In addition, surface-coated scaffolds are generally non-injectable. Here, it is demonstrated that cationic polymer condensed nucleic acids can be effectively loaded into injectable granular hydrogel scaffolds by stabilizing the condensed nucleic acid into a lyophilized powder, loading the powder into a bulk hydrogel, and then fragmenting the loaded hydrogel. The resulting hydrogel microparticles contain non-aggregated nucleic acid particles, can be annealed post-injection to result in an injectable microporous hydrogel, and can effectively deliver nucleic acids to embedded cells with a constant expression rate. Due to the nature of granular hydrogels, it is demonstrated that mixtures of loaded and unloaded particles and spatially resolved gene expression can be easily achieved. The ability to express genes long term from an injectable porous hydrogel will further open the applications of nucleic acid delivery.
DNMT3A R882 Mutation in Human Haematopoietic Stem Cells Alters Differentiation Towards Neutrophils and Monocytes
Authors: Aditi Vedi, Daniel Hayler, Tamir Biezuner, Antonella Santoro, Kendig Sham, Amos Tuval, Adi Danin, Yoni Moskovitz, Liran I. Shlush, Elisa Laurenti
Journal: Blood (2021)
The Associations between Coping Strategy Use and Patient-Reported Outcomes in Patients with Acute Myeloid Leukemia
Authors: Matthew J. Reynolds, Monica Bodd, Ashley Nelson, Richard Newcomb, P. Connor Johnson, Tejaswini Dhawale, Lauren Heuer, Sabah Gillani, Daniel Yang, Emma C. Deary, Elizabeth Daskalakis, Lauren Goldschen, Andrew M. Brunner, Amir T. Fathi, Thomas W. LeBlanc, Areej El-Jawahri, Hermioni L. Amonoo
Journal: Blood (2021)
Comparative Study of Unrelated and Haploidentical Donor Hematopoietic Cell Transplant for Chronic Myeloid Leukemia with Post Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis: A Study from the Chronic Malignancies Working Party of EBMT
Authors: Guillermo Ortí, Luuk Gras, Nienke Zinger, Aleksandr D. Kulagin, Jennifer Byrne, Jane F Apperley, Kazimierz Halaburda, Igor Wolfgang Blau, Andrew Clark, Nicolaus Kröger, Laimonas Griskevicius, Kristina Carlson, Matthew P. Collin, Adrian Bloor, Emanuele Angelucci, Didier Blaise, Mahmoud Aljurf, Lucia Lopez Corral, Achilles Anagnostopoulos, Yves Beguin, Tomasz Wrobel, Luigi Rigacci, Patrick John Hayden, Yves Chalandon, Ibrahim Yakoub-Agha
Journal: Blood (2021)
Global Plan Targets Elimination of Bacterial Meningitis Epidemics
Authors: Bridget M. Kuehn
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal